Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

Stopped This study was voluntarily terminated due to a business decision not to proceed, and not due to any safety issue.

Conditions

• Sickle Cell Disease

Interventions

• BIOLOGICAL: MGTA-145
• DRUG: Plerixafor

Sponsor

Ensoma

Collaborators

• [object Object]